drugset
drugset / Trial / NCT00075439

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

NCT00075439 ↗

Phase 2 Completed 90 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Timeline

Start
2003-12
Primary completion
2007-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — Oral

Indications

PPoma gastrin-producing neuroendocrine tumor glucagonoma pancreatic cholera pancreatic endocrine carcinoma pancreatic insulinoma somatostatinoma